Closing Reflections and Key Takeaways of Optimizing Treatment Selection and Sequencing in Advanced EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Emerging Evidence

May 11, 2026

Post-TTLC 2026: Dr. Doroshow steps back and asks Dr. Patel for the single most important insight or data point likely to change his clinical practice in the near term. Dr. Patel returns to a foundational message: precision therapy is impossible without a precision diagnosis. He stresses the importance of identifying not only canonical EGFR mutations (exon 19 deletions and L858R) but also distinguishing them from EGFR exon 20 insertions, where some agents are useful and others are not. Understanding the patient’s full molecular landscape determines whether FLAURA2, MARIPOSA, or osimertinib monotherapy is most appropriate, and these upfront decisions have downstream consequences in later lines of treatment. None of those conversations can begin without comprehensive upfront molecular testing.

Dr. Doroshow expands on a theme she raised earlier: a treatment cannot work unless the patient can take it regularly. That includes not only managing toxicity, but also the frequency and time commitment of treatment and whether insurance coverage produces a tolerable copay. She has seen outrageous copays with oral therapies and tries to check in regularly with patients about financial toxicity — a conversation she believes clinicians do not have often enough.

Dr. Patel closes by thanking Dr. Doroshow and the audience for joining this OncLive discussion on optimizing treatment selection and sequencing in advanced EGFR-mutated non-small cell lung cancer (NSCLC), balancing efficacy, toxicity, and emerging evidence, expressing hope that the discussion offered valuable perspective to guide clinical decision-making and improve outcomes for patients with lung cancer.